According to an article published in the Journal of the American Association, there is a documented risk of gastrointestinal adverse events associated with the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss, including medications like Ozempic
The presence of tremor at rest, rigidity, bradykinesia, and postural instability (instability of balance) are considered the hallmark motor features of idiopathic Parkinsons disease (PD)
Following the aforementioned incidents, the development of lotiglipron was discontinued, and drug regulatory agencies in several countries classified GLP-1RAs as a potential risk factor for thyroid cancer, gallbladder, and biliary diseases
Loud noise exposure represents a widespread cause of sensorineural hearing loss and it has been demonstrated that it not only damages the organ of Corti, but also the cochlear nerve
GLP-1 receptor agonist medicines such as Wegovy (semaglutide) or Mounjaro (tirzepatide) are designed to be taken once weekly
Shen Z, Lu P, Jin W, et al